Redefining response in overactive bladder syndrome

BJU International

Volumn 99, Issue 1, 2007, Pages 101-106

  Payne, Christopher K ^a   Kelleher, Con ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Composite endpoint; King's Health Questionnaire; Overactive bladder syndrome; Quality of life; Response; Solifenacin

Indexed keywords

PLACEBO; SOLIFENACIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

DOUBLE-BLIND METHOD; HUMANS; MULTICENTER STUDIES; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; QUESTIONNAIRES; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 33845507882     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06517.x     Document Type: Article

References (21)

1. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
2. Abrams P. Introduction: Overactive bladder and its treatments. Urology 2000; 55: 1-2
3. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002; 60(Suppl. 5): 7-12
4. Wein AJ. Diagnosis and treatment of the overactive bladder. Urology 2003; 62 (Suppl. 5): 20-7
5. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002; 187: 116-26
6. Diokno AC, Appell RA, Sand PK et al.; OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95
7. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-9
8. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414-21
9. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S; Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-5
10. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 335-40
11. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
12. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo-controlled trial of once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-24
13. Chapple CR, Rechberger T, Al-Shukri S et al; YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10
14. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997; 104: 1374-9
15. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95: 81-5
16. Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH. How much is enough and who says so? BJOG 2004; 111: 605-12
17. Cardozo L, Robinson D, Drogendijk T. Solifenacin statistically significantly increased continence rates in subjects with symptoms of overactive bladder syndrome. Presented at ICS, Paris 2004: Abstract 141
18. Chapple CR, Wyndaele J, Gronen S. Solifenacin provided statistically significant and clinically relevant reductions in urgency, a defining symptom of overactive bladder. Presented at ICS, Paris 2004: Abstract 276
19. Blaivas JG. Outcome measures for urinary incontinence. Urology 1998; 51 (Suppl. 2A): 11-9
20. Rodriguez LV, Blander DS, Dorey F, Raz S, Zimmern P. Discrepancy in patient and physician perception of patient's quality of life related to urinary symptoms. Urology 2003; 62: 49-53
21. Palmtag H. The patient's perspective: redefining end points. Urology 2004; 64 (Suppl. 6): 17-20